45S5 Bioglass bonds directly to bone by growing its own hydroxyapatite layer
45S5 Bioglass — invented by Larry Hench in 1969 — is a silicate glass scaffold engineered with an open, interconnected pore network that mimics cancellous bone, allowing cells and fluid to permeate the implant from the moment of placement.
The 45S5 formulation sits in a narrow compositional window discovered by Hench: high Na2O and CaO content relative to SiO2, plus a CaO/P2O5 ratio kept low, so that the glass network is loose enough to react rapidly with body fluid rather than remaining chemically inert like conventional silicate or borosilicate glasses.
Interconnected macropores (100-500 microns) allow vascular ingrowth, osteoprogenitor cell migration, and nutrient diffusion throughout the scaffold volume, not just at the outer surface. Pore architecture is tuned to approximate the porosity of trabecular bone.
Unlike inert implant materials (titanium, alumina, most polymers), which become walled off by fibrous scar tissue, Bioglass is engineered to be recognized and remodeled by the body as if it were a mineral extension of bone itself.
Within seconds of implantation, extracellular fluid wicks into the pore network and begins wetting the glass surface, initiating the cascade of surface reactions that define bioactivity.
The first and fastest reaction stage: modifier cations at the glass surface swap places with hydrogen-bearing ions from solution, alkalinizing the local microenvironment and priming the network for hydrolysis.
Na+ (and some Ca2+) ions in the glass exchange with H+ and H3O+ ions from the surrounding fluid: Si-O-Na+ + H+ → Si-OH + Na+(solution) This is diffusion-controlled and extremely fast, raising local pH as hydrogen ions are consumed from solution.
The elevated pH attacks the silica network itself, hydrolyzing Si-O-Si bridging bonds: Si-O-Si + H2O → Si-OH + HO-Si Soluble silica (as Si(OH)4) is released into solution, and the glass surface is left covered by a silanol-rich, hydrated gel layer that is structurally porous but no longer crystalline glass.
Xynos et al. (2000) showed that dissolution products — soluble Si, Ca, Na and P ions released at this stage — are not just structural byproducts; they act as biochemical signals that upregulate osteoblast genes such as osteocalcin and alkaline phosphatase, priming nearby cells for bone formation even before mineralization begins.
This dual action — providing both a mineral-bonding surface and a soluble ionic signal — is why Bioglass is described as osteoconductive AND osteostimulative, a combination rare among synthetic biomaterials.
As the silica gel layer polycondenses into a more ordered, porous SiO2-rich film, calcium and phosphate ions — drawn from both the dissolving glass and the surrounding physiological fluid — begin depositing onto its surface.
Silanol groups on adjacent gel chains condense, releasing water and rebuilding a more mechanically coherent, porous SiO2-rich surface layer: Si-OH + HO-Si → Si-O-Si + H2O This layer acts as a nucleation template for mineral deposition rather than a barrier to it.
Ca2+ and PO4^3- ions migrate through the fluid-filled gel pores and accumulate at the surface, forming an amorphous calcium phosphate (ACP) film. Because both ions are supplied from the dissolving glass itself and from the surrounding body fluid, the local Ca/P ratio at the surface climbs steadily toward the ratio found in bone mineral.
Unlike a simple surface coating, this ACP film is chemically continuous with the underlying silica gel, which is why the eventual mineral layer bonds rather than merely adheres to the glass substrate.
The amorphous calcium phosphate film crystallizes into carbonated hydroxyapatite (HCA) — chemically and structurally close to the mineral phase of natural bone — and begins physically incorporating collagen fibrils from the surrounding tissue.
The ACP film crystallizes into carbonated hydroxyapatite, Ca10(PO4,CO3)6(OH)2 — the same mineral phase, with the same carbonate substitutions, found in natural bone apatite. Crystallization proceeds from nucleation sites outward, thickening the mineral layer over 1-3 days.
As HCA crystals grow, collagen fibrils secreted by nearby osteoblasts and osteoprogenitor cells become physically embedded within the growing mineral layer, exactly as occurs during natural bone mineralization. This interpenetration is what creates a genuine chemical bond rather than a mechanical interlock.
This is the defining property that separates bioactive materials from bioinert ones: the interface is not a boundary between two different materials, but a continuous gradient from glass to gel to HCA to living bone.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| 45S5 Bioglass | Trabecular & cortical bone | Full 5-stage dissolution → HCA layer in 1-3 days | Fastest bonding rate; also osteostimulative via ion release |
| S53P4 Bioglass | Sinus/mastoid, orthopedic voids | Similar HCA formation, slower dissolution than 45S5 | Antibacterial silica-ion effect; slower resorption |
| Hydroxyapatite ceramic | Load-bearing defect filling | Surface dissolution/reprecipitation, no glass network | High crystallinity, very slow resorption, mechanically stable |
| Tricalcium phosphate (TCP) | Resorbable bone void filler | Dissolves and is replaced by new bone over months | Fully resorbable; matches remodeling timescale |
Osteoblasts deposit new bone matrix directly onto the HCA layer, extending inward from host bone, while the glass scaffold itself is progressively dissolved and resorbed — ideally at a rate matched to new bone ingrowth.
Degradation rate is tunable via glass composition (e.g., adding network-stabilizing oxides slows dissolution). Scaffolds are designed so the rate of resorption tracks the rate of new bone ingrowth: mechanical support is not lost prematurely, and inert material does not persist unnecessarily once its structural role is complete.
The HCA surface provides an osteoconductive scaffold — a physical template new bone can grow along — while the continuous release of Si, Ca, P and Na ions provides an osteostimulative signal that drives osteoprogenitor proliferation and differentiation, first characterized by Xynos and colleagues in 2000.
45S5 Bioglass and its derivatives are used clinically in bone graft substitutes, dental and orthopedic defect repair, and sinus/mastoid obliteration, valued for direct bone bonding without the fibrous encapsulation typical of bioinert implants such as titanium or alumina.
The end state is not a coated implant sitting inside bone — it is a continuous, chemically bonded interface where scaffold-derived mineral and host bone mineral are structurally indistinguishable.